

Akums introduces enhanced Gabapentin ER formulation for Postherpetic Neuralgia management

15 December 2025 | News

Gabapentin remains a well-established therapy for neuropathic pain, but conventional formulations often require multiple daily doses



Akums Drugs & Pharmaceuticals, a Delhi-based Contract Development and Manufacturing Organization (CDMO), has announced the rollout of its enhanced Gabapentin Extended-Release (ER) formulation for the management of Postherpetic Neuralgia (PHN).

PHN, a chronic neuropathic pain condition that can persist for months after a shingles outbreak, affects nearly 10–20% of patients and becomes increasingly debilitating with age.

Gabapentin remains a well-established therapy for neuropathic pain, but conventional formulations often require multiple daily doses and may be associated with variable absorption. Akums' new ER variant incorporates the company's proprietary RetenEx Technology, engineered to provide a gradual, sustained release of the drug along the targeted region of the gastrointestinal tract. This approach optimises absorption, minimises peak-related side effects, and supports once-daily dosing—a significant advantage for elderly patients who typically struggle with complex medication schedules.

Positioned as an advanced, patient-centric formulation, Akums' Gabapentin ER 300 mg and 600 mg tablets are DCGI approved and designed to enhance treatment adherence without compromising safety or efficacy. The ER profile may also help maintain more consistent plasma levels, reducing the fluctuations that often contribute to breakthrough pain.

"In chronic pain conditions like PHN, even small improvements in convenience and daily functioning can transform a patient's quality of life. Our focus with this enhanced Gabapentin ER formulation is to offer a solution that is not only effective but also easier to maintain for long durations, especially for elderly individuals who often manage multiple therapies. With the integration of our RetenEx Technology, we aim to support more stable pain control through sustained drug release and once-daily dosing," said Sandeep Jain, Managing Director and Founder, Akums Drugs & Pharmaceuticals Ltd.